Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
vorinostat
Class :
Antineoplastics and HDAc Inhibitors
Brand Name :
No Data Available.
Synonyms :
vorinostat
Class :
Antineoplastics and HDAc Inhibitors
Dosage Forms & Strengths Â
capsule Â
100mg Â
Indicated for the treatment of CTCL, who have progressive, persistent, or recurrent disease on or followed by two systemic therapies :
400
mg
Orally
once a day
the dose is reduced to 300 mg orally per day if the patient is intolerant to therapy
the dose was further reduced to 300 mg once daily for five consecutive days each week if needed
continue the treatment until progressive disease or unacceptable toxicity occurs
Dose Adjustments
Renal Dose Adjustments:
Caution recommended.
Liver Dose Adjustments:
starting dose reduced to 300 mg orally once daily for mild to moderate hepatic impairment bilirubin 1-3 x ULN or AST > ULN
Data not available for severe hepatic impairment bilirubin > 3 x ULN
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, there may be an increased risk of adverse effects   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when used together, entrectinib and vorinostat both increase the QTc interval
when used together, encorafenib and vorinostat both increase the QTc interval
may have an increasingly adverse effect when combined with taurursodiol
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, vorinostat reduces the effects of the cholera vaccine by immunosuppressive effects   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, both increase the QTC interval   
It may enhance QTc interval when combined with lithium
hepatitis A vaccine inactivatedÂ
combining vorinostat with the Hepatitis A Vaccine may reduce its therapeutic efficacy
methoxypolyethylene glycol-epoetin betaÂ
combining vorinostat with methoxy polyethylene glycol-epoetin beta can raise the risk or severity of thrombosis
when combined with prenylamine, there is an increased risk or severity of QTc prolongation
the danger or seriousness of adverse effects can be increased when stepronin is combined with vorinostat
when both drugs are combined, there may be increased toxicity of vorinostat by QTC interval   
when both drugs are combined, there may be increased toxicity of vorinostat by QTC interval 
Vorinostat is a selective histone deacetylase (HDAC) inhibitor that targets HDAC1, HDAC2, HDAC3 (Class I), and HDAC6 (Class II). By preventing the removal of acetyl groups from histones, it leads to the accumulation of acetylated histones, resulting in relaxed chromatin and reactivation of suppressed genes. This induces cell cycle arrest and/or apoptosis in some cancer cells. Its antitumor effect involves epigenetic modulation, though the exact mechanism is not fully understood.Â
Adverse drug reactions: Â
Frequency defined Â
>10%Â
Anorexia Â
Alopecia Â
Anemia  Â
Peripheral edema  Â
Headache  Â
Pruritus  Â
Cough  Â
Chills Â
Constipation Â
Dry mouth Â
Dysguesia Â
Diarrhea  Â
Fatigue Â
Nausea  Â
Thrombocytopenia Â
Weight loss Â
Muscle spasms Â
Increase serum Cr Â
Dizziness  Â
Vomiting  Â
Upper respiratory infection  Â
Decreased appetite Â
Pyrexia Â
<10% Â
Prolonged QT interval  Â
Pulmonary embolism  Â
Â
NoneÂ
ContraindicationÂ
Hepatic impairmentÂ
CautionsÂ
Before starting treatment, correct any existing hypokalemia or hypomagnesemia, and avoid use in patients with congenital long QT syndrome or those taking other QT-prolonging drugs or with conditions that prolong QT interval.Â
Monitor blood counts every 2 weeks for the first 2 months, then monthly, due to risk of thrombocytopenia and anemia, which may require dose adjustment or discontinuation. Severe thrombocytopenia with GI bleeding has been reported with HDAC inhibitors like valproic acid—monitor platelets closely if used concurrently.Â
Monitor for signs of pulmonary embolism or deep vein thrombosis (DVT) during therapy.Â
Use caution in diabetic patients, as hyperglycemia may occur; check blood glucose every 2 weeks initially, then monthly.Â
Be aware of dose-dependent anemia and thrombocytopenia—adjust or stop treatment as needed.Â
Use with valproic acid or coumarin anticoagulants may increase risks; monitor accordingly.Â
Pregnancy warnings:   Â
Breastfeeding warnings:Â
Pregnancy Categories:     Â
Â
Vorinostat is a histone deacetylase (HDAC) inhibitor used to treat cutaneous T-cell lymphoma (CTCL). It blocks HDAC enzymes that normally remove acetyl groups from histones, causing increased acetylation. This relaxes the chromatin structure, enabling the activation of tumor suppressor genes, which can result in cell cycle arrest and/or apoptosis in cancerous cells.Â
PharmacokineticsÂ
AbsorptionÂ
Peak plasma concentration reached in approximately 4 hours after oral dosing. At a 400 mg dose, peak plasma concentration averages 1.2 ± 0.62 µmol/L. Absorption is faster in the fasted state, but with a lower overall exposure (AUC) and peak concentration. Taking vorinostat with a high-fat meal increases absorption by about 33%. Oral bioavailability is approximately 43%.Â
DistributionÂ
About 71% of the drug is bound to plasma proteins.Â
MetabolismÂ
Metabolized primarily in the liver. Produces inactive metabolites.Â
Elimination/ExcretionÂ
Terminal half-life is approximately 2 hours. Excreted mainly via the urine (52%).Â
PharmacodynamicsÂ
Vorinostat inhibits histone deacetylase, leading to the buildup of acetylated histones, which triggers cell cycle arrest and/or apoptosis in certain cancer cells. Â
Vorinostat is administered orally and should be taken with food to enhance absorption and reduce gastrointestinal discomfort. It is important to maintain adequate hydration by drinking at least 2 liters of fluids daily during treatment.Â
Generic Name: vorinostatÂ
Pronounced: vo-RIN-oh-statÂ
Why do we use vorinostat? Â
Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL), a cancer affecting specific white blood cells that causes skin lesions. It is prescribed for cases where CTCL has progressed, persisted, or recurred after treatment with other medications.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
